US FDA approves Tibotec's HIV drug Edurant
This article was originally published in Scrip
Executive Summary
Johnson & Johnson subsidiary Tibotec Pharmaceuticals on 20 May won US approval for Edurant (rilpivirine) in combination with other antiretroviral drugs as a therapy for treatment-naïve adults with HIV-1 infection.